Risk for ILD/Pneumonitis Examined for Trastuzumab Deruxtecan; Pooled analysis of data from phase I and II studies used to evaluate AE of interstitial lung disease/pneumonitis associated with T-Dxd.

Media coverage

• Title	Risk for ILD/Pneumonitis Examined for Trastuzumab Deruxtecan; Pooled analysis of data from phase I and II studies used to evaluate AE of interstitial lung disease/pneumonitis associated with T-Dxd.
  Media name/outlet	Physician's Briefings
  Country/Territory	United States
  Date	22/08/22
  Persons	Charles Powell